Dr. Swaminathan P. Iyer, is a Professor of Medicine in the Department of Lymphoma/Myeloma at University of Texas, MD Anderson. After completing medical training at Bangalore Medical College in India, Dr. Iyer completed his residency in internal medicine at Wayne State University. He completed his fellowship in hematology and oncology at the University of Miami. He is a physician scientist with extensive expertise in clinical studies particularly in Hematological Malignancies such as leukemia and lymphoma, in addition to laboratory interests in developing small molecules, aptamers and drug delivery technologies such as nanoparticles into the clinic, he has led many trials including first-in-man studies, exploration of different doses and schedules of administration and investigational agent combinations, and the examination of biomarkers for patient selection. He was part of pivotal studies that led to the FDA approval of the new anti-CD20 monoclonal antibody Ofatumumab or Arzerra in Chronic Lymphocytic Leukemia. He leads the T cell lymphoma program at MD Anderson. His laboratory interests are in developing aptamers against targets in hematological malignancies.